Table 1.
Expression of inflammasome components examined by reverse transcription–polymerase chain reaction in arthritic synovium from osteoarthritis (OA) and rheumatoid arthritis (RA) patients
| OA | RA | OA | RA | ||
|---|---|---|---|---|---|
| NALP1 | 11/11 | 8/9 | NALP10 | 10/10 | 7/9 |
| NALP2 | 3/11 | 5/9 | NALP11 | 3/10 | 5/9 |
| NALP3 | 11/11 | 9/9 | NALP12 | 8/11 | 7/9 |
| NALP4 | 4/11 | 5/9 | NALP13 | 0/11 | 0/9 |
| NALP5 | 0/11 | 0/9 | NALP14 | 9/10 | 8/9 |
| NALP6 | 9/11 | 9/9 | ASC | 11/11 | 9/9 |
| NALP7 | 3/10 | 3/9 | Caspase-1 | 8/11 | 7/9 |
| NALP8 | 4/11 | 5/9 | Caspase-5 | 7/9 | 8/9 |
| NALP9 | 1/10 | 1/9 | Pro-IL-18 | 10/10 | 9/9 |
| Pro-IL-1β | 7/11 | 6/9 |
Expression of NACHT, LRR and PYD domains containing proteins (NALPs) 1–14, apoptosis-associated speck-like protein containing a CARD domain (ASC), caspase 1 and caspase 5 messenger RNA in synovial tissue from patients with RA and OA undergoing joint replacement surgery, as determined by reverse transcription–polymerase chain reaction. Before this, normalization of the samples was performed with glyceraldehyde 3-phosphate dehydrogenase to control for cellularity. Data are presented as the number of positive expressing tissues over the total number of biopsies analysed (at least nine patients per group).